3.42
price up icon13.62%   0.41
after-market Handel nachbörslich: 3.35 -0.07 -2.05%
loading
Schlusskurs vom Vortag:
$3.01
Offen:
$3.06
24-Stunden-Volumen:
5.82M
Relative Volume:
1.18
Marktkapitalisierung:
$898.21M
Einnahmen:
$194.75M
Nettoeinkommen (Verlust:
$-51.26M
KGV:
-12.21
EPS:
-0.28
Netto-Cashflow:
$-23.38M
1W Leistung:
-8.06%
1M Leistung:
-7.82%
6M Leistung:
+59.81%
1J Leistung:
+187.39%
1-Tages-Spanne:
Value
$3.03
$3.42
1-Wochen-Bereich:
Value
$2.92
$3.79
52-Wochen-Spanne:
Value
$1.11
$4.0787

Akebia Therapeutics Inc Stock (AKBA) Company Profile

Name
Firmenname
Akebia Therapeutics Inc
Name
Telefon
617-871-2098
Name
Adresse
245 FIRST STREET, CAMBRIDGE, MA
Name
Mitarbeiter
181
Name
Twitter
@akebiatx
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
AKBA's Discussions on Twitter

Vergleichen Sie AKBA mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Drug Manufacturers - Specialty & Generic icon
AKBA
Akebia Therapeutics Inc
3.42 994.08M 194.75M -51.26M -23.38M -0.28
Drug Manufacturers - Specialty & Generic icon
ZTS
Zoetis Inc
147.35 64.93B 9.39B 2.61B 2.22B 5.81
Drug Manufacturers - Specialty & Generic icon
TAK
Takeda Pharmaceutical Co Adr
14.44 45.07B 29.98B 958.27M 5.31B 0.2964
Drug Manufacturers - Specialty & Generic icon
HLN
Haleon Plc Adr
9.54 41.53B 14.35B 1.85B 0 0.4023
Drug Manufacturers - Specialty & Generic icon
TEVA
Teva Pharmaceutical Industries Ltd Adr
16.37 18.37B 16.54B -1.64B 749.00M -1.45
Drug Manufacturers - Specialty & Generic icon
UTHR
United Therapeutics Corp
301.50 13.68B 2.99B 1.21B 1.13B 25.06

Akebia Therapeutics Inc Stock (AKBA) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2025-06-04 Fortgesetzt H.C. Wainwright Buy
2025-04-28 Eingeleitet Leerink Partners Outperform
2025-04-01 Eingeleitet Jefferies Buy
2023-11-29 Fortgesetzt BTIG Research Buy
2023-08-28 Hochstufung H.C. Wainwright Neutral → Buy
2023-05-31 Hochstufung Piper Sandler Neutral → Overweight
2022-03-31 Herabstufung H.C. Wainwright Buy → Neutral
2022-03-31 Herabstufung Mizuho Buy → Neutral
2022-03-31 Herabstufung Needham Buy → Hold
2022-03-31 Herabstufung Piper Sandler Overweight → Neutral
2021-03-08 Eingeleitet Cantor Fitzgerald Overweight
2021-01-29 Herabstufung JP Morgan Neutral → Underweight
2019-11-14 Bestätigt Needham Buy
2019-08-06 Bestätigt H.C. Wainwright Buy
2019-07-11 Bestätigt H.C. Wainwright Buy
2019-05-02 Eingeleitet JP Morgan Overweight
2019-03-20 Eingeleitet Citigroup Neutral
2018-09-07 Fortgesetzt Morgan Stanley Equal-Weight
2018-08-10 Bestätigt Needham Buy
2018-06-06 Bestätigt H.C. Wainwright Buy
2017-12-19 Eingeleitet Piper Jaffray Overweight
2017-12-07 Eingeleitet BTIG Research Buy
2017-09-15 Eingeleitet RBC Capital Mkts Sector Perform
2017-07-10 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt H.C. Wainwright Buy
2017-04-27 Bestätigt Needham Buy
2016-12-27 Bestätigt H.C. Wainwright Buy
2016-12-20 Bestätigt JMP Securities Mkt Outperform
2016-11-15 Eingeleitet Aegis Capital Buy
2016-09-29 Eingeleitet Brean Capital Buy
2016-03-16 Bestätigt Needham Buy
2016-01-21 Eingeleitet Credit Suisse Neutral
Alle ansehen

Akebia Therapeutics Inc Aktie (AKBA) Neueste Nachrichten

pulisher
Aug 10, 2025

The Akebia Therapeutics, Inc. (NASDAQ:AKBA) Second-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance

Aug 10, 2025
pulisher
Aug 10, 2025

Is Akebia Therapeutics (NASDAQ:AKBA) A Risky Investment? - simplywall.st

Aug 10, 2025
pulisher
Aug 10, 2025

How moving averages guide Akebia Therapeutics Inc. tradingIntraday Signal Forecast for Fast Traders - Newser

Aug 10, 2025
pulisher
Aug 09, 2025

Identifying reversal signals in Akebia Therapeutics Inc.Free Optimized Watchlist With Daily Adjustments - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

What’s next for Akebia Therapeutics Inc. stock priceFree Growth Based Stock Signal Screener - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Akebia outlines access to over 275,000 dialysis patients for Vafseo in Q4 as DaVita pilot launches - MSN

Aug 09, 2025
pulisher
Aug 09, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Q2 2025 Earnings Call Transcript - Insider Monkey

Aug 09, 2025
pulisher
Aug 09, 2025

Akebia Therapeutics Second Quarter 2025 Earnings: EPS: US$0.001 (vs US$0.041 loss in 2Q 2024) - Yahoo Finance

Aug 09, 2025
pulisher
Aug 09, 2025

Akebia Therapeutics Inc. stock trend outlook and recovery pathAsset Growth Pattern and Return Summary - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

What does recent volatility data suggest for Akebia Therapeutics Inc.Free Oversold Bounce Stock Play Ideas - Newser

Aug 09, 2025
pulisher
Aug 09, 2025

Akebia Therapeutics Reports Strong Q2 2025 Growth - The Globe and Mail

Aug 09, 2025
pulisher
Aug 08, 2025

Using Bollinger Bands to evaluate Akebia Therapeutics Inc.Trend Following Ideas with Volume Confirmation - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Is Akebia Therapeutics Inc. reversing from oversold territoryFree Real Profit Trade Plan Suggestions - Newser

Aug 08, 2025
pulisher
Aug 08, 2025

Akebia Therapeutics (AKBA.O) Surges 9.14% — No Technical Signals Fired, But Why? - AInvest

Aug 08, 2025
pulisher
Aug 08, 2025

Akebia Therapeutics, Inc. (NASDAQ:AKBA) Given Average Rating of “Buy” by Analysts - Defense World

Aug 08, 2025
pulisher
Aug 08, 2025

Akebia (AKBA) Prepares for Q2 Earnings Announcement - GuruFocus

Aug 08, 2025
pulisher
Aug 08, 2025

Akebia Therapeutics Inc (AKBA) Q2 2025 Earnings Call Highlights: Record Revenue and Strategic Growth Initiatives - GuruFocus

Aug 08, 2025
pulisher
Aug 07, 2025

Akebia's Q2 2025 Earnings Call: Unpacking Contradictions in Vafseo Trends, Auryxia Revenue, and FDA Strategies - AInvest

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia (AKBA) Q2 Revenue Jumps 43% - AOL.com

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics Inc reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics Inc (AKBA) Stock: 52-Week Performance Insights and Trading Volume - investchronicle.com

Aug 07, 2025
pulisher
Aug 07, 2025

Earnings call transcript: Akebia Ther Q2 2025 earnings miss, stock drops By Investing.com - Investing.com Canada

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business Highlights - GlobeNewswire

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics (AKBA) Reports Break-Even Earnings for Q2 - Yahoo Finance

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics, Inc. SEC 10-Q Report - TradingView

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics Q2 revenue smashes expectations - MarketScreener

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics Inc Q2 2025 Earnings: Revenue Surges to $62. - GuruFocus

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia reports Q2 EPS 0c vs (4c) last year - TipRanks

Aug 07, 2025
pulisher
Aug 07, 2025

Akebia Therapeutics to Present at Canaccord Genuity’s 45th Annual Growth Conference - GlobeNewswire

Aug 07, 2025
pulisher
Aug 06, 2025

Akebia Q2 2025 Earnings Preview - MSN

Aug 06, 2025
pulisher
Aug 06, 2025

Akebia Therapeutics CEO to Discuss Kidney Disease Innovations at Major Growth Conference - Stock Titan

Aug 06, 2025
pulisher
Aug 06, 2025

Chart based exit strategy for Akebia Therapeutics Inc.Market Downturn Defense Strategy Analysis - Newser

Aug 06, 2025
pulisher
Aug 05, 2025

Akebia Therapeutics Inc expected to post a loss of 2 cents a shareEarnings Preview - TradingView

Aug 05, 2025
pulisher
Aug 04, 2025

Akebia Therapeutics (AKBA) Grants Stock Options to New Employees - MSN

Aug 04, 2025
pulisher
Aug 04, 2025

Leerink Partners Reiterates a Buy Rating on Akebia Therapeutics (AKBA) With a $7 PT - MSN

Aug 04, 2025
pulisher
Aug 04, 2025

Akebia Initiates Vafseo® (vadadustat) Post-Marketing Study in Conjunction with Large Dialysis Organization - GlobeNewswire

Aug 04, 2025
pulisher
Aug 04, 2025

Price momentum metrics for Akebia Therapeutics Inc. explainedFree Alpha Focused Technical Trade Signals - Newser

Aug 04, 2025
pulisher
Aug 03, 2025

Is it the right time to buy Akebia Therapeutics Inc. stockCapitalize on high-growth stocks early - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are the technical indicators suggesting about Akebia Therapeutics Inc.Invest confidently with real-time data analysis - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What are analysts’ price targets for Akebia Therapeutics Inc. in the next 12 monthsInvest confidently with expert support - Jammu Links News

Aug 03, 2025
pulisher
Aug 03, 2025

What institutional investors are buying Akebia Therapeutics Inc. stockBuild a portfolio that outperforms consistently - Jammu Links News

Aug 03, 2025
pulisher
Aug 02, 2025

When is Akebia Therapeutics Inc. stock expected to show significant growthUnlock high-yield investment opportunities - Jammu Links News

Aug 02, 2025
pulisher
Aug 02, 2025

How Akebia Therapeutics Inc. stock performs during market volatilityFree Entry Zone Strategy for Consistent Profit - Newser

Aug 02, 2025
pulisher
Aug 02, 2025

Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Aug 02, 2025
pulisher
Aug 01, 2025

Akebia Therapeutics Awards $880K Worth of Stock Options in Strategic New Employee Package - Stock Titan

Aug 01, 2025
pulisher
Aug 01, 2025

Order Book Volume Tilts Bullish on Akebia Therapeutics Inc.Entry Zone Strategy for Consistent Profit Shared - metal.it

Aug 01, 2025
pulisher
Aug 01, 2025

Are Medical Stocks Lagging Akebia Therapeutics (AKBA) This Year? - Yahoo Finance

Aug 01, 2025
pulisher
Jul 31, 2025

Would Akebia Therapeutics (NASDAQ:AKBA) Be Better Off With Less Debt? - 富途牛牛

Jul 31, 2025
pulisher
Jul 31, 2025

Akebia Therapeutics to Report Second Quarter 2025 Financial Results and Discuss Recent Business Highlights - 富途牛牛

Jul 31, 2025
pulisher
Jul 31, 2025

Should I hold or sell Akebia Therapeutics Inc. stock in 2025Market Forecast Opportunities For Beginners - Jammu Links News

Jul 31, 2025

Finanzdaten der Akebia Therapeutics Inc-Aktie (AKBA)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading
$26.71
price up icon 0.43%
$16.67
price up icon 1.15%
$9.70
price up icon 3.30%
drug_manufacturers_specialty_generic RDY
$13.80
price up icon 1.47%
$125.01
price down icon 0.47%
$301.50
price up icon 0.69%
Kapitalisierung:     |  Volumen (24h):